Jazz Pharmaceuticals plc (Nasdaq: JAZZ) (“Jazz” or the “Company”) today announced that Philip Johnson has been appointed Executive Vice President and Chief Financial Officer, effective March 1, 2024.
|
[21-February-2024] |
Mr. Johnson Brings Over 35 Years of Financial and Operating Experience to Leadership Team DUBLIN, Feb. 21, 2024 /PRNewswire/ -- Jazz Pharmaceuticals, Inc. (Nasdaq: JAZZ) (“Jazz” or the “Company”) today announced that Philip Johnson has been appointed Executive Vice President and Chief Financial Officer, effective March 1, 2024. Mr. Johnson succeeds Renée Galá, who was promoted to President and Chief Operating Officer in October 2023. Mr. Johnson joins Jazz Pharmaceuticals with over 35 years of financial experience, most recently leading Eli Lilly and Company’s treasury and investor relations operations as Group Vice President of Finance. In his new role, Mr. Johnson will oversee financial reporting, accounting, tax, treasury, risk management, financial planning and analysis, information services and facilities. He will also oversee the Company’s investor relations and corporate development functions. “Phil’s deep financial acumen, strategic mindset and proven leadership abilities are an ideal fit for Jazz. Phil’s appointment follows a comprehensive search process to identify the right financial leader as we continue to execute against our strategy to grow and diversify our global business,” said Bruce Cozadd, Chairman and Chief Executive Officer of Jazz Pharmaceuticals. “I am thrilled to welcome Phil to Jazz and look forward to working closely with him to deliver enhanced shareholder value.” “Jazz is a highly respected company with a strong financial foundation and significant opportunities for growth and value creation. It is exciting to join an innovative and science-driven organization deeply committed to addressing the unmet needs of patients who may have limited treatment options,” said Phil Johnson. “I am thrilled to bring my cross-functional expertise to my new role and build upon the team’s momentum to continue to grow and diversify Jazz’s global business.” About Philip Johnson About Jazz Pharmaceuticals plc Contacts: Investors: Media:
View original content to download multimedia:https://www.prnewswire.com/news-releases/jazz-pharmaceuticals-appoints-philip-johnson-as-chief-financial-officer-302066697.html SOURCE Jazz Pharmaceuticals plc | ||
Company Codes: NASDAQ-NMS:JAZZ |